First Infant Desensitization to Liposomal Amphotericin B
The Journal of Pediatric Pharmacology and Therapeutics · 2026-06 · 31 (3) · 432-436
DOI: 10.5863/jppt-25-00078 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pediatric Pharmacology and Therapeutics, 2026-06. Verfasst von Maryam Rostamyan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases (MR), Hakim Children's Hospital, Tehran University of Medical Sciences, Tehran, Iran. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Liposomal amphotericin B is the first-line treatment for Visceral leishmaniasis ; however, drug hypersensitivity reactions, such as anaphylaxis, can pose significant challenges. Desensitization protocols are an option when alternative treatments are lacking. A 7-month-old female infant presented with persistent fever, pallor, splenomegaly, and laboratory findings suggestive of Visceral leishmaniasis with secondary hemophagocytic lymphohistiocytosis (HLH). After developing anaphylaxis following the first dose of liposomal amphotericin B (3 mg/kg), a 14-step desensitization protocol was successfully implemented, allowing continuation of therapy without complications. After completing the course of treatment, the patient’s fever resolved, spleen size normalized, and hematological parameters improved. Causality assessment using the Naranjo scale indicated a “probable” adverse drug reaction (score = 6). This case represents the first reported successful use of a standard liposomal amphotericin B desensitization protocol in an infant under 1 year, demonstrating its feasibility and safety in managing anaphylaxis in endemic areas.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases (MR), Hakim Children's Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Allergy and Immunology (SC), Hakim Children's Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Infectious Diseases (MK), Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Hematology and Oncology (FK), Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Zitieren
APA
Rostamyan, M., Chinehkesh, S., Khodabandeh, M., & Kompani, F. (2026). First Infant Desensitization to Liposomal Amphotericin B. The Journal of Pediatric Pharmacology and Therapeutics, 31(3), 432-436. https://doi.org/10.5863/jppt-25-00078
Vancouver
Rostamyan M, Chinehkesh S, Khodabandeh M, Kompani F. First Infant Desensitization to Liposomal Amphotericin B. The Journal of Pediatric Pharmacology and Therapeutics. 2026;31(3):432-436. doi:10.5863/jppt-25-00078
BibTeX
@article{Rostamyan2026,
author = {Rostamyan, Maryam and Chinehkesh, Shirin and Khodabandeh, Mahmoud and Kompani, Farzad},
title = {First Infant Desensitization to Liposomal Amphotericin B},
journal = {The Journal of Pediatric Pharmacology and Therapeutics},
year = {2026},
volume = {31},
number = {3},
pages = {432--436},
doi = {10.5863/jppt-25-00078}
}
EUVIMED